Poly(ADP-ribose) Polymerase 1 is Inhibited by a Histone H2A Variant, MacroH2A, and Contributes to Silencing of the Inactive X Chromosome
Overview
Authors
Affiliations
Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme that is involved in modulating chromatin structure, regulation of gene expression, and sensing DNA damage. Here, we report that PARP-1 enzymatic activity is inhibited by macroH2A, a vertebrate histone H2A variant that is enriched on facultative heterochromatin. MacroH2A family members have a large C-terminal non-histone domain (NHD) and H2A-like histone domain. MacroH2A1.2 and PARP-1 interact in vivo and in vitro via the NHD. The NHD of each macroH2A family member was sufficient to inhibit PARP-1 enzymatic activity in vitro. The NHD of macroH2A1.2 was a mixed inhibitor of PARP-1 catalytic activity, with affects on both catalytic activity and the substrate binding affinity of PARP-1. Depletion of PARP-1 by RNA interference caused reactivation of a reporter gene on the inactive X chromosome, demonstrating that PARP-1 participates in the maintenance of silencing. These results suggest that one function of macroH2A in gene silencing is to inhibit PARP-1 enzymatic activity, and this may affect PARP-1 association with chromatin.
Ouararhni K, Mietton F, Sabir J, Ibrahim A, Molla A, Albheyri R BMC Biol. 2024; 22(1):188.
PMID: 39218869 PMC: 11368025. DOI: 10.1186/s12915-024-01987-x.
Roles of Histone H2A Variants in Cancer Development, Prognosis, and Treatment.
Lai P, Chan K Int J Mol Sci. 2024; 25(6).
PMID: 38542118 PMC: 10969971. DOI: 10.3390/ijms25063144.
PARP1: Liaison of Chromatin Remodeling and Transcription.
Zong W, Gong Y, Sun W, Li T, Wang Z Cancers (Basel). 2022; 14(17).
PMID: 36077699 PMC: 9454564. DOI: 10.3390/cancers14174162.
Hou X, Cai C, He Y, An S, Zhao S, Sun H Front Cell Dev Biol. 2022; 10:799042.
PMID: 35178387 PMC: 8844553. DOI: 10.3389/fcell.2022.799042.
PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Kontandreopoulou C, Diamantopoulos P, Tiblalexi D, Giannakopoulou N, Viniou N Blood Adv. 2021; 5(22):4794-4805.
PMID: 34529761 PMC: 8759124. DOI: 10.1182/bloodadvances.2021004638.